GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

Cambridge: Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

Deutsche Bank downgraded GSK (GSK) to Hold from Buy with a price target of 1,350 GBp, down from 1,700 GBp. The firm cites President-elect ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...

Jitters over the health of the UK economy have been fuelled by today’s weaker-than-expected GDP release.September’s 0.1% ...

GSK collaborates closely with Canadian sites — such as hospitals and other health-care centres — to operationalize its trials ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Deutsche Bank analyst Emmanuel Papadakis downgraded GSK (GSK) to Hold from Buy with a price target of 1,350 GBp, down from 1,700 GBp.

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...